Patent ID: 6224897
Filing Date: 2001-05-01
Classification: A61K,Y10S

Abstract:
A patient-controlled method of treatment to abate tobacco use in humans, said method comprising:(a) applying to the skin of a human at least one transdermal nicotine patch device comprising a total absorbable nicotine dose to be determined by the human which is effective to abate nicotine withdrawal symptoms, wherein the total absorbable nicotine dose does not exceed about 66 mg and does not induce nicotine excess symptoms;(b) about 16 to about 24 hours after application of the transdermal nicotine patch device in Step (a), removing the transdermal nicotine patch device applied in Step (a) and applying to the skin of the human at least one transdermal nicotine patch device comprising a total absorbable nicotine dose to be determined by the human which is effective to abate nicotine withdrawal symptoms, wherein the total absorbable nicotine dose does not exceed about 66 mg and does not induce nicotine excess symptoms, provided that the total absorbable nicotine dose in Step (b) is greater than the total absorbable nicotine dose in Step (a);(c) about 16 to about 24 hours after application of the transdermal nicotine patch device in Step (b), removing the transdermal nicotine patch device applied in Step (b) and applying to the skin of the human at least one transdermal nicotine patch device comprising a total absorbable nicotine dose to be determined by the human which is effective to abate nicotine withdrawal symptoms, wherein the total absorbable nicotine dose does not exceed about 66 mg and does not induce nicotine excess symptoms, provided that the total absorbable nicotine dose in Step (c) is greater than the total absorbable nicotine dose in Step (b);(d) about 16 to about 24 hours after application of the transdermal nicotine patch device in Step (c), removing the transdermal nicotine patch device applied in Step (c) and for a first continuous period of time, beginning with the commencement of treatment and continuing for about six weeks therefrom, applying to the skin of the human at an interval of about 24 hours at least one transdermal nicotine patch device comprising a total absorbable nicotine dose to be determined by the human which is effective to abate nicotine withdrawal symptoms, wherein the total absorbable nicotine dose does not exceed about 66 mg and does not induce nicotine excess symptoms, and removing the transdermal nicotine patch device about 16 to about 24 hours after application thereof, provided that the total absorbable nicotine dose in Step (d) is less than or equal to the total absorbable nicotine dose in Step (c);(e) after completion of the first continuous period of time, applying to the skin of the human at least one transdermal nicotine patch device comprising a total absorbable nicotine dose to be determined by the human which is effective to abate nicotine withdrawal symptoms, wherein the total absorbable nicotine dose does not exceed about 42 mg and does not induce nicotine excess symptoms;(f) about 16 to about 24 hours after application of the transdermal nicotine patch device in Step (e), removing the transdermal nicotine patch device applied in Step (e) and for a second continuous period of time, beginning with the application in Step (e) and continuing for about two weeks therefrom, applying to the skin of the human at an interval of about 24 hours at least one transdermal nicotine patch device comprising a total absorbable nicotine dose to be determined by the human which is effective to abate nicotine withdrawal symptoms, wherein the total absorbable nicotine dose does not exceed about 42 mg and does not induce nicotine excess symptoms, and removing the transdermal nicotine patch device about 16 to about 24 hours after application thereof;(g) after completion of the second continuous period of time, applying to the skin of the human at least one transdermal nicotine patch device comprising a total absorbable nicotine dose to be determined by the human which is effective to abate nicotine withdrawal symptoms, wherein the total absorbable nicotine dose does not exceed about 21 mg and does not induce nicotine excess symptoms;(h) about 16 to about 24 hours after application of the transdermal nicotine patch device in Step (g), removing the transdermal nicotine patch device applied in Step (g) and for a third continuous period of time, beginning with the application in Step (g) and continuing for about two weeks therefrom, applying to the skin of the human at an interval of about 24 hours at least one transdermal nicotine patch device comprising a total absorbable nicotine dose to be determined by the human which is effective to abate nicotine withdrawal symptoms, wherein the total absorbable nicotine dose does not exceed about 21 mg and does not induce nicotine excess symptoms, and removing the transdermal nicotine patch device about 16 to about 24 hours after application thereof; and(i) after completion of the third continuous period of time, the human abstains from using any transdermal nicotine patch device or tobacco for at least seven days, provided that in at least one of Steps (b)-(h), the total absorbable nicotine dose is greater than the total absorbable nicotine dose in the prior step.